"Epoprostenol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
| Descriptor ID |
D011464
|
| MeSH Number(s) |
D10.251.355.255.550.550.500 D23.469.050.175.725.550.500
|
| Concept/Terms |
Epoprostenol- Epoprostenol
- PGI2
- Prostaglandin I2
- Prostacyclin
- Prostaglandin I(2)
- Epoprostanol
- PGX
Epoprostenol Sodium- Epoprostenol Sodium
- Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
|
Below are MeSH descriptors whose meaning is more general than "Epoprostenol".
Below are MeSH descriptors whose meaning is more specific than "Epoprostenol".
This graph shows the total number of publications written about "Epoprostenol" by people in this website by year, and whether "Epoprostenol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 3 | 0 | 3 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epoprostenol" by people in Profiles.
-
Bosch NA, Law AC, Vail EA, Gillmeyer KR, Gershengorn HB, Wunsch H, Walkey AJ. Inhaled Nitric Oxide vs?Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation. Chest. 2022 Dec; 162(6):1287-1296.
-
Toomey D, O'Brien M, Hayes BD, Wilcox S. A retrospective review of implementation of an inhaled epoprostenol protocol in the emergency department. Am J Emerg Med. 2022 08; 58:210-214.
-
Richards JB, Frakes M, Saia MS, Johnson R, Wilcox SR. Changes in Oxygen Saturation and Mean Arterial Pressure With Inhaled Epoprostenol in Transport. J Intensive Care Med. 2021 Jul; 36(7):758-765.
-
Foster C, Frakes MA, Puopolo E, McNulty F, Saia MS, Hourihan M, Flynn M, Wilcox SR. Inhaled Epoprostenol to Facilitate Safe Transport in Legionnaires' Disease. Prehosp Disaster Med. 2020 Feb; 35(1):109-114.
-
Ling QL, Akasaka H, Chen C, Haile CN, Winoske K, Ruan KH. The Protective Effects of Up-Regulating Prostacyclin Biosynthesis on Neuron Survival in Hippocampus. J Neuroimmune Pharmacol. 2020 06; 15(2):292-308.
-
Parikh KS, Dahhan T, Nicholl L, Ruopp N, Pomann GM, Fortin T, Tapson VF, Rajagopal S. Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension. Sci Rep. 2019 03 11; 9(1):4061.
-
Ling QL, Murdoch E, Ruan KH. How can we address the controversies surrounding the use of NSAIDS in neurodegeneration? Future Med Chem. 2016 07; 8(11):1153-5.
-
Merideth FL, Quinn DK. "Walking the Walk": Decisional Capacity Deficits After Right Hemisphere Subdural Hematoma. Psychosomatics. 2016 Jan-Feb; 57(1):102-6.
-
Walkey AJ, Fein D, Horbowicz KJ, Farber HW. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther. 2011 Aug; 24(4):421-5.
-
Raghunathan K, Connelly NR, Robbins LD, Ganim R, Hochheiser G, DiCampli R. Inhaled epoprostenol during one-lung ventilation. Ann Thorac Surg. 2010 Mar; 89(3):981-3.